Related Experiment Video
Updated: Apr 30, 2026
09:02
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
2.2K
Development of novel nanoparticle for bone cancer
Journal of Biomedical Nanotechnology
|May 9, 2014
Summary
Novel polymeric nanoparticles improve targeted delivery of ethylenediamine-tetramethylenephosphonic acid (EDTMP) for bone metastasis treatment. These nanoparticles accumulate in bone tissue, offering prolonged release and potentially better pain management for patients.
Area of Science:
- Oncology
- Radiopharmaceuticals
- Nanomedicine
Background:
- Bone metastasis accounts for nearly all bone tumors, with current treatments focusing on palliative care.
- Ethylenediamine-tetramethylenephosphonic acid (EDTMP) labeled with Samarium-153 is used to improve survival but suffers from superficial delivery requiring multiple doses.
Purpose of the Study:
- To develop and evaluate novel polymeric nanoparticles of EDTMP for improved in vivo biodistribution.
- To assess the potential of these nanoparticles as a more effective treatment for bone metastasis pain.
Main Methods:
- Polymeric nanoparticles of EDTMP were synthesized using a double emulsion-solvent evaporation technique.
- Nanoparticles were characterized using atomic force microscopy (AFM).
- Technetium-99m was used to label nanoparticles for in vivo biodistribution studies in Wistar rats.
Main Results:
- The synthesized nanoparticles ranged from 200-500 nm in size.
- Polymeric EDTMP nanoparticles demonstrated prolonged accumulation in bone tissue (up to 150 minutes).
- Sustained release of EDTMP from nanoparticles at the target site was observed.
Conclusions:
- Novel polymeric nanoparticles offer enhanced targeted delivery of EDTMP compared to free EDTMP.
- This formulation shows promise for improved management of bone metastasis pain through prolonged drug release at the bone site.
